VACCINE DEVELOPMENT

Vaccines have significantly reduced the threat of diseases that were once widespread and oftentimes fatal. Today, more people benefit from vaccines than ever before – and the list of diseases that vaccines can help prevent continues to grow.

In addition to vaccines for viruses and bacteria, biopharmaceutical companies are researching how vaccines can impact dementia, cancer, and other areas of significant disease. This has made recruitment more challenging, as target populations include patients with the disease or at high risk for the disease. Some of these populations can be very difficult to identify.

Other vaccine studies require the participation of adolescents or even children. With many parents and physicians not wanting young people to be vaccinated, it can be hard to locate enough patients to conduct a successful trial.

At Bioclinica, we rise above vaccine recruitment challenges to find the patients you want at the speed you need.

Global Patient Recruitment
The Bioclinica Research Network has significant experience in successfully recruiting for vaccine research. We are able to draw on more than 1,000,000 potential study participants through databases and online patient and caregiver communities, including access to both healthy and therapeutically-aligned volunteers. Over the past five years, Bioclinica has contributed to 25+ vaccine trials with superior retention rates.

We are well-positioned to find qualified participants for vaccine studies as our sites operate in 14 countries across four continents: Europe, North America, South America, and Asia, with a dedicated SMO service in China that is focused on delivery of qualified patients. Because our network covers both the northern and southern hemispheres, we are able to help you find qualified subjects at any time and in any location. You can therefore address seasonal illnesses (such as the flu) around the world in a timely manner.
Phase I Research
The Bioclinica Research Network is equipped to conduct Phase I studies for both healthy and special populations. We have run a number of Phase I vaccine studies across the globe for both adult and elderly populations.

Best-in-Class Sites
Our investigator sites are unified by globalized standard operating procedures (SOPs) and quality systems, yielding the highest quality data. Each site is staffed by medical experts and trained professionals – therapeutic-area specialists, physicians, nurses, study coordinators, raters, and technicians – and has a full array of medical testing equipment.

We are experienced with all routes of administration including oral (pill/liquid), patch, electroporation, intramuscular, intradermal, microneedle, transdermal, and intranasal, and have proven expertise across adult, adolescent, elderly, and at-risk patient populations.

Find QUALIFIED SUBJECTS at any time in any location around the world

LEVERAGE THE Bioclinica Advantage
The Bioclinica Research Network simplifies the complexity and solves the challenges associated with vaccine clinical trials. Whatever stage your vaccine research is in (Phase I-IV), we can assist you with our global network of established, readily-available investigator sites and our extensive patient recruitment capabilities. With best-in-class SOPs and quality systems in place, you will receive outstanding results and deep insights for your vaccine clinical trials.